@article{f9f6f1c466814ac58c2ffa03788c7ddf,
title = "Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice",
author = "M. Frueh and O.E. Rahma and R.K. Pachynski and J. Mazieres and J. Goldschmidt and T.G.N. Ton and S.K. Mhatre and C.-Y. Chuo and J. Martinalbo and J. Davies and R. Juergens",
note = "Background: In the randomised Ph III OAK study, atezo (anti-PD-L1) significantly improved survival vs docetaxel, regardless of PD-L1 levels, and was approved by the FDA and EMA as 2L+ tx for advanced NSCLC. Given limited real-world data (RWD) on atezo in clinical practice, we describe here tx and characteristics of pts receiving atezo in clinical practice.",
year = "2019",
month = apr,
day = "1",
doi = "10.1093/ANNONC/MDZ063.077",
language = "American English",
volume = "30",
journal = "Annals of Oncology",
issn = "1569-8041",
publisher = "Elsevier",
}